Acetazolamide for Cystoid Macular Oedema in Bietti Crystalline Retinal Dystrophy.
10.3341/kjo.2014.28.2.189
- Author:
Geoffrey K BROADHEAD
1
;
Andrew A CHANG
Author Information
1. Sydney Institute of Vision Science, Sydney, Australia. achang@sydneyretina.com.au
- Publication Type:Case Reports
- Keywords:
Acetazolamide;
Bietti crystalline dystrophy;
Macular edema;
Optical coherence tomography
- MeSH:
Acetazolamide/*administration & dosage;
Administration, Oral;
Adult;
Corneal Dystrophies, Hereditary/*drug therapy/pathology;
Diuretics/*administration & dosage;
Humans;
Macular Edema/*drug therapy/pathology;
Male;
Retinal Diseases/*drug therapy/pathology;
Tomography, Optical Coherence;
Treatment Outcome
- From:Korean Journal of Ophthalmology
2014;28(2):189-191
- CountryRepublic of Korea
- Language:English
-
Abstract:
Bietti crystalline retinal dystrophy is a rare, inherited disorder whose hallmark is the presence of retinal crystal deposits associated with later chorioretinal degeneration. This condition may rarely be complicated by the development of cystoid macular oedema leading to rapid visual decline. Currently, treatment options for this complication of Bietti dystrophy are limited and the visual prognosis is poor. Here, we present a case of cystoid macular oedema associated with Bietti dystrophy that was successfully diagnosed using multimodal imaging techniques including optical coherence tomography and fluorescein angiography. These modalities confirmed the diagnosis of macular oedema and excluded other possible causes of oedema such as choroidal neovascularisation. In this patient, cystoid macular oedema was resolved with oral acetazolamide therapy, a treatment that has not been previously reported in this context. Acetazolamide treatment resulted in oedema resolution and improvement in visual function, and can be considered a therapeutic option for other patients with Bietti dystrophy who develop cystoid macular oedema.
